Peptide Vaccines for Leishmaniasis
Due to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subuni...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.01043/full |
| _version_ | 1818429572223336448 |
|---|---|
| author | Rory C. F. De Brito Rory C. F. De Brito Jamille M. De O. Cardoso Levi E. S. Reis Levi E. S. Reis Joao F. Vieira Fernando A. S. Mathias Bruno M. Roatt Bruno M. Roatt Bruno M. Roatt Rodrigo Dian D. O. Aguiar-Soares Jeronimo C. Ruiz Jeronimo C. Ruiz Daniela de M. Resende Daniela de M. Resende Alexandre B. Reis Alexandre B. Reis Alexandre B. Reis |
| author_facet | Rory C. F. De Brito Rory C. F. De Brito Jamille M. De O. Cardoso Levi E. S. Reis Levi E. S. Reis Joao F. Vieira Fernando A. S. Mathias Bruno M. Roatt Bruno M. Roatt Bruno M. Roatt Rodrigo Dian D. O. Aguiar-Soares Jeronimo C. Ruiz Jeronimo C. Ruiz Daniela de M. Resende Daniela de M. Resende Alexandre B. Reis Alexandre B. Reis Alexandre B. Reis |
| author_sort | Rory C. F. De Brito |
| collection | DOAJ |
| description | Due to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subunits. Nevertheless, the use of whole parasite or their subunits for vaccine production has numerous disadvantages. Therefore, the use of Leishmania peptides to design more specific vaccines against leishmaniases seems promising. Moreover, peptides have several benefits in comparison with other kinds of antigens, for instance, good stability, absence of potentially damaging materials, antigen low complexity, and low-cost to scale up. By contrast, peptides are poor immunogenic alone, and they need to be delivered correctly. In this context, several approaches described in this review are useful to solve these drawbacks. Approaches, such as, peptides in combination with potent adjuvants, cellular vaccinations, adenovirus, polyepitopes, or DNA vaccines have been used to develop peptide-based vaccines. Recent advancements in peptide vaccine design, chimeric, or polypeptide vaccines and nanovaccines based on particles attached or formulated with antigenic components or peptides have been increasingly employed to drive a specific immune response. In this review, we briefly summarize the old, current, and future stands on peptide-based vaccines, describing the disadvantages and benefits associated with them. We also propose possible approaches to overcome the related weaknesses of synthetic vaccines and suggest future guidelines for their development. |
| first_indexed | 2024-12-14T15:19:39Z |
| format | Article |
| id | doaj.art-355544afe97f4caea50c91fec2c0707f |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-14T15:19:39Z |
| publishDate | 2018-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-355544afe97f4caea50c91fec2c0707f2022-12-21T22:56:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-05-01910.3389/fimmu.2018.01043350145Peptide Vaccines for LeishmaniasisRory C. F. De Brito0Rory C. F. De Brito1Jamille M. De O. Cardoso2Levi E. S. Reis3Levi E. S. Reis4Joao F. Vieira5Fernando A. S. Mathias6Bruno M. Roatt7Bruno M. Roatt8Bruno M. Roatt9Rodrigo Dian D. O. Aguiar-Soares10Jeronimo C. Ruiz11Jeronimo C. Ruiz12Daniela de M. Resende13Daniela de M. Resende14Alexandre B. Reis15Alexandre B. Reis16Alexandre B. Reis17Laboratório de Pesquisas Clínicas, Programa de Pós-graduação em Ciências Farmacêuticas/CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Pesquisas Clínicas, Programa de Pós-graduação em Ciências Farmacêuticas/CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Pesquisas Clínicas, Programa de Pós-graduação em Ciências Farmacêuticas/CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilInstituto Nacional de Ciência e Tecnologia em Doenças Tropicais, Salvador, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilGrupo Informática de Biossistemas e Genômica, Programa de Pós-graduação em Ciências da Saúde, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, BrazilPrograma de Pós-graduação em Biologia Computacional e Sistemas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, BrazilGrupo Informática de Biossistemas e Genômica, Programa de Pós-graduação em Ciências da Saúde, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, BrazilPrograma de Pós-graduação em Biologia Computacional e Sistemas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, BrazilLaboratório de Pesquisas Clínicas, Programa de Pós-graduação em Ciências Farmacêuticas/CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, BrazilLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, BrazilInstituto Nacional de Ciência e Tecnologia em Doenças Tropicais, Salvador, BrazilDue to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subunits. Nevertheless, the use of whole parasite or their subunits for vaccine production has numerous disadvantages. Therefore, the use of Leishmania peptides to design more specific vaccines against leishmaniases seems promising. Moreover, peptides have several benefits in comparison with other kinds of antigens, for instance, good stability, absence of potentially damaging materials, antigen low complexity, and low-cost to scale up. By contrast, peptides are poor immunogenic alone, and they need to be delivered correctly. In this context, several approaches described in this review are useful to solve these drawbacks. Approaches, such as, peptides in combination with potent adjuvants, cellular vaccinations, adenovirus, polyepitopes, or DNA vaccines have been used to develop peptide-based vaccines. Recent advancements in peptide vaccine design, chimeric, or polypeptide vaccines and nanovaccines based on particles attached or formulated with antigenic components or peptides have been increasingly employed to drive a specific immune response. In this review, we briefly summarize the old, current, and future stands on peptide-based vaccines, describing the disadvantages and benefits associated with them. We also propose possible approaches to overcome the related weaknesses of synthetic vaccines and suggest future guidelines for their development.http://journal.frontiersin.org/article/10.3389/fimmu.2018.01043/fullpeptide-based vaccineschimeric vaccinepolypeptide vaccinestegumentary leishmaniasesvisceral leishmaniasis |
| spellingShingle | Rory C. F. De Brito Rory C. F. De Brito Jamille M. De O. Cardoso Levi E. S. Reis Levi E. S. Reis Joao F. Vieira Fernando A. S. Mathias Bruno M. Roatt Bruno M. Roatt Bruno M. Roatt Rodrigo Dian D. O. Aguiar-Soares Jeronimo C. Ruiz Jeronimo C. Ruiz Daniela de M. Resende Daniela de M. Resende Alexandre B. Reis Alexandre B. Reis Alexandre B. Reis Peptide Vaccines for Leishmaniasis Frontiers in Immunology peptide-based vaccines chimeric vaccine polypeptide vaccines tegumentary leishmaniases visceral leishmaniasis |
| title | Peptide Vaccines for Leishmaniasis |
| title_full | Peptide Vaccines for Leishmaniasis |
| title_fullStr | Peptide Vaccines for Leishmaniasis |
| title_full_unstemmed | Peptide Vaccines for Leishmaniasis |
| title_short | Peptide Vaccines for Leishmaniasis |
| title_sort | peptide vaccines for leishmaniasis |
| topic | peptide-based vaccines chimeric vaccine polypeptide vaccines tegumentary leishmaniases visceral leishmaniasis |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2018.01043/full |
| work_keys_str_mv | AT rorycfdebrito peptidevaccinesforleishmaniasis AT rorycfdebrito peptidevaccinesforleishmaniasis AT jamillemdeocardoso peptidevaccinesforleishmaniasis AT leviesreis peptidevaccinesforleishmaniasis AT leviesreis peptidevaccinesforleishmaniasis AT joaofvieira peptidevaccinesforleishmaniasis AT fernandoasmathias peptidevaccinesforleishmaniasis AT brunomroatt peptidevaccinesforleishmaniasis AT brunomroatt peptidevaccinesforleishmaniasis AT brunomroatt peptidevaccinesforleishmaniasis AT rodrigodiandoaguiarsoares peptidevaccinesforleishmaniasis AT jeronimocruiz peptidevaccinesforleishmaniasis AT jeronimocruiz peptidevaccinesforleishmaniasis AT danielademresende peptidevaccinesforleishmaniasis AT danielademresende peptidevaccinesforleishmaniasis AT alexandrebreis peptidevaccinesforleishmaniasis AT alexandrebreis peptidevaccinesforleishmaniasis AT alexandrebreis peptidevaccinesforleishmaniasis |